Results 51 to 60 of about 644,370 (183)

The use of aromatase inhibitors in boys with short stature: what to know before prescribing?

Archives of Endocrinology and Metabolism
Aromatase is a cytochrome P450 enzyme (CYP19A1 isoform) able to catalyze the conversion of androgens to estrogens. The aromatase gene mutations highlighted the action of estrogen as one of the main regulators of bone maturation and closure of bone plate.
Alessandra Linardi, Durval Damiani, Carlos A. Longui   +2 more
doaj   +1 more source

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study

Frontiers in Oncology
BackgroundAromatase inhibitors have been successfully employed in clinical practice for the treatment of breast cancer (BC); however, the accompanying tendon disorders has often been underestimated.
Shuai Zhao, Lu-Yao Xu, Ping Chen, Su Zhang, Kai-Li Mao   +4 more
doaj   +1 more source

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]

, 2010
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker   +2 more
core   +1 more source

QSAR analysis of some azole derivatives as potent aromatase inhibitors [PDF]

Trends in Pharmaceutical Sciences, 2018
A high proportion of breast tumors are hormone-dependent, implying that endogenous estrogens play a critical role in cancer cell proliferation. One of the most effective strategies for the treatment of breast cancer is reduction of estrogens level by ...
Razeih Sabet, Soghra Khabnadideh, Samaneh Mohseni, Ayyub Mojaddami, Zahra Rezaei   +4 more
doaj  

Whole Body Vibration Exposure on Markers of Bone Turnover, Body Composition, and Physical Functioning in Breast Cancer Patients Receiving Aromatase Inhibitor Therapy: A Randomized Controlled Trial

Integrative Cancer Therapies, 2018
Introduction: Women with breast cancer are often prescribed aromatase inhibitors, which can cause rapid loss of bone mass leading to significant potential for morbidity.
Michael K. Baker PhD, Carolyn J. Peddle-McIntyre PhD, Daniel A. Galvão PhD, Catherine Hunt AD, Nigel Spry MBBS, PhD, Robert U. Newton PhD   +5 more
doaj   +1 more source

Treatment of endometriosis by aromatase inhibitors: efficacy and side effects [PDF]

, 2010
The recent demonstration that aromatase is expressed at higher levels in endometriosis implants than in normal endometrium has led to pilot studies using inhibitor aromatasis in patients with endometriosis.
Hoppé, Emmanuel, Legrand, Erick, Catala, Laurent, A.C. Racine, Sentilhes, Loic, E. Legrand, L. Catala, Lefebvre-Lacoeuille, Céline, C. Lefebvre-Lacoeuille, P. Descamps, Descamps, Philippe, E. Hoppé, L. Sentilhes, Racine, A-C   +13 more
core   +1 more source

Discovery and Evaluation of Novel Sulfonamide Derivatives Targeting Aromatase in ER+ Breast Cancer

Pharmaceuticals
Background: Third-generation aromatase inhibitors (CYP19A1) are the mainstay of treatment for estrogen-receptor-positive breast cancer. This is because estrogen is required for cancer growth in approximately 70% of patients with this condition.
Barbara De Filippis, Mariangela Agamennone, Alessandra Ammazzalorso, Rosa Amoroso, Letizia Giampietro, Cristina Maccallini, Begüm Nurpelin Sağlık, Chiara De Simone, Mariachiara Zuccarini, Zafer Asım Kaplancıklı, Marialuigia Fantacuzzi   +10 more
doaj   +1 more source

Bilateral De Quervain Syndrome after Aromatase Inhibitor Administration: A Case Report and Review of the Literature

Case Reports in Medicine, 2012
Aromatase inhibitors are widely used as one of the main treatment options of both early and advanced hormone receptor-positive breast cancer in postmenopausal women.
Konstantinos Papadimitriou, Panteleimon Kountourakis, Emmanouil Morakis, Vassilios Vassiliou, Vasileios Barbounis, Alexandros Ardavanis   +5 more
doaj   +1 more source

Nonsteroidal aromatase inhibitors: Recent advances

, 2002
Aromatase is the cytochrome P450 enzyme responsible for the last step of estrogen biosynthesis, and aromatase inhibitors constitute an important class of drugs in clinical use for the treatment of breast cancer.
Recanatini M., Cavalli A., Valenti P.
core   +1 more source

Impact of aromatase inhibitors on thyroid function in postmenopausal women with early-stage breast cancer: a prospective controlled study

Cancer Treatment and Research Communications
Purpose: Aromatase inhibitors are commonly used in adjuvant therapy for breast cancer. However, their impact on thyroid function remains unclear. This study aimed to evaluate thyroid function in postmenopausal women with oestrogen-receptor-positive early-
Djordje Marina, August Nielsen, Kristian Buch-Larsen, Michael Andersson, Åse Krogh Rasmussen, Peter Schwarz   +5 more
doaj   +1 more source